Characterizing complex and competing drug–drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine

The fixed‐dose combination of the direct acting antivirals glecaprevir (GLE) and pibrentasvir (PIB) is an oral, once‐daily treatment for all six major genotypes of chronic hepatitis C virus infection. A single and multiple‐dose rifampin study (N = 12) and a carbamazepine study (N = 12) were conducte...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosloski, Matthew P., Li, Hong, Wang, Stanley, Mensa, Federico, Kort, Jens, Liu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087067/
https://www.ncbi.nlm.nih.gov/pubmed/36597378
http://dx.doi.org/10.1111/cts.13471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087067/
https://www.ncbi.nlm.nih.gov/pubmed/36597378
http://dx.doi.org/10.1111/cts.13471

Ejemplares similares